Purification of Filaggrin from Human Epidermis and Measurement of Antifilaggrin Autoantibodies in Sera from Patients with Rheumatoid Arthritis by an Enzyme-Linked Immunosorbent AssayPalosuo T.a · Lukka M.a · Alenius H.a, b · Kalkkinen N.c · Aho K.a · Kurki P.d · Heikkilä R.d · Nykänen M.a · von Essen R.e
aNational Public Health Institute, bInstitute of Occupational Health, cInstitute of Biotechnology, University of Helsinki and dUnited Laboratories, Helsinki, and eRheumatism Foundation Hospital, Heinola, Finland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: The so-called antikeratin antibody (AKA) and the antiperinuclear factor (APF) that recognize proteins related to human epidermal filaggrin belong to the most specific serological markers of rheumatoid arthritis (RA). However, assays for the detection of AKA and APF are currently based on immunofluorescence, a method that is subject to arbitrary interpretation and inadequate standardization of the substrates. Methods: Proteins extracted from human epidermis were separated by reversed-phase high-performance liquid chromatography (HPLC). Filaggrin-containing fractions, identified in immunoblotting by monoclonal antifilaggrin antibodies, were then subjected to gel filtration HPLC and, finally, to a second reversed-phase HPLC step. Tryptic digestion, amino acid sequencing and mass spectrometry were used to cornfirm the identity of the purified protein. Filaggrin was used as antigen in enzyme-linked immunosorbent assay (ELISA) to measure IgG class antifilaggrin antibodies. Results: The filaggrin preparation obtained gave a single band in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, binding monoclonal antifilaggrin antibody in immunoblotting. Amino acid sequences of all 10 tryptic peptides analyzed were shown to originate from human filaggrin. Antifilaggrin antibody levels exceeded the 99th percentile level of 100 middle-aged blood donors in 26/55 (47%) RA sera. At a similar cutoff level 28/55 (51%) of the RA sera were positive in the AKA test. Of the 26 antifilaggrin-positive sera, 21 were also AKA-positive. Conclusion: Human filaggrin can be purified by standard biochemical techniques, despite the heterogeneity of the protein, and used in ELISA for testing autoantibodies to filaggrin. The sensitivity of the assay equals that of the AKA test.
- Aho K, Palosuo T, Kurki P: Marker antibodies of rheumatoid arthritis: Diagnostic and pathogenetic implications. Semin Arthritis Rheum 1994;23:379–387.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.
Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ: Antikeratin antibodies in rheumatoid arthritis. Br Med J 1979;ii:97–99.
Nienhuis RL, Mandena E: A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. Ann Rheum Dis 1964;23:202–205.
Hoet RMA, Boerbooms AMT, Arends M, Ruiter DJ, van Venrooij WJ: Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: Colocalization of the perinuclear factor and profilaggrin. Ann Rheum Dis 1991;50:259–264.
- Simon M, Girbal E, Sebagg M, Gomès-Daudrix V, Vincent C, Salama G, Serre G: The cytokeratin filament-aggregating protein filaggrin is the target of the so-called ‘antikeratin autoantibodies’, autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993;92:1387–1393.
- Sebagg M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, Serre G: The antiperinuclear factor and the so-called anti-keratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995;95:2672–2679.
- Girbal-Neuhauser E, Montézin M, Croute F, Sebbag M, Simon M, Durieux JJ, Serre G: Normal human keratinocytes express in vitro specific molecular forms of (pro)filaggrin recognized by rheumatoid arthritis-associated anti-filaggrin autoantibodies. Mol Med 1997;3:145–156.
- Dale BA, Ling SY: Immunologic cross-reaction of stratum corneum basic protein and a keratohyalin granule protein. J Invest Dermatol 1979;72:257–261.
- Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
- Kurki P, Aho K, Palosuo T, Heliövaara M: Immunopathology of rheumatoid arthritis: Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35:914–917.
- Nykänen M, Palosuo T, Aho K, Sahi T, von Essen R: Improved immunoturbidimetric method for rheumatoid factor testing. J Clin Pathol 1993;46:1065–1066.
- Feltkamp TEW, Berhelot JM, Boerbooms AMT, Geerzen HGM, Hoet R, De Keyser F, van Venrooij WJ, Verbruggen G, Veys EM, Youinou P: Interlaboratory variability of the perinuclear factor (APF) test for rheumatoid arthritis. Clin Exp Rheumatol 1993;11:57–59.
- McKinley-Grant LJ, Idler WW, Bernstein IA, Parry DAD, Cannizzarro L, Groce CM, Huebner K, Lessin SR, Steinert PM: Characterization of a cDNA clone encoding human filaggrin and localization of the gene to chromosome region 1q21. Proc Natl Acad Sci 1989;86:4848–4852.
- Presland RB, Haydock PV, Fleckman P, Nirunsuksiri W, Dale BA: Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus. J Biol Chem 1992;267:23772–23781.
- Scott IR, Harding CR, Barret JG: Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta 1982;719:110–117.
Gan SQ, McBride OW, Idler WW, Markova N, Steinert PM: Organization, structure and polymorphisms of the human profilaggrin. Biochemistry 1990;29:9432–9440.
- Thulin CD, Taylor JA, Walsh KA: Microheterogeneity of human filaggrin: Analysis of a complex peptide mixture using mass spectrometry. Protein Sci 1996;5:1157–1164.
Serre G, Vincent C: Filaggrin (keratin) autoantibodies; in Peter JB, Shoenfeld Y (eds): Autoantibodies. Amsterdam, Elsevier Science, 1996, pp 271–272.
- Resing KA, Walsh KA, Haugen-Scofield J, Dale BA: Identification of proteolytic cleavage sites in the conversion of profilaggrin to filaggrin in mammalian epidermis. J Biol Chem 1989;264:1837–1845.
Berthelot JM, Maugars Y, Prost A, Youinou P: Rheumatoid arthritis and filaggrin. A review. Rev Rhum 1995;62:127–138.
- Harding CR, Scott IR: Histidine-rich proteins (filaggrins): Structural and functional heterogeneity during epidermal differentiation. J Mol Biol 1983;170:651–673.
- Gomès-Daudrix V, Sebbag M, Girbal E, Vincent C, Simon R, Rakotoarivony J, Abbal M, Fournié B, Serre G: Immunoblotting detection of so-called ‘antikeratin antibodies’: A new assay for the diagnosis of rheumatoid arthritis. Ann Rheum Dis 1994;53:735–742.
- Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M: Antikeratin antibodies: Diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992;51:743–746.
- Berthelot JM, Maugars Y, Castagné A, Audrain M, Prost A: Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled. Ann Rheum Dis 1997;56:123–125.
Aho K, von Essen R, Kurki P, Palosuo T, Heliövaara M: Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993;34:1278–1281.
- Kurki P, von Essen R, Kaarela K, Isomäki H, Palosuo T, Aho K: Antibody to stratum corneum (antikeratin antibody) and antiperinuclear factor: Markers for progressive rheumatoid arthritis. Scand J Rheumatol 1997;26:346–349.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.